{"id":816846,"date":"2025-02-24T10:47:36","date_gmt":"2025-02-24T15:47:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-transforms-multiomic-research-with-new-technologies-to-unlock-deeper-understanding-of-biology\/"},"modified":"2025-02-24T10:47:36","modified_gmt":"2025-02-24T15:47:36","slug":"illumina-transforms-multiomic-research-with-new-technologies-to-unlock-deeper-understanding-of-biology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-transforms-multiomic-research-with-new-technologies-to-unlock-deeper-understanding-of-biology\/","title":{"rendered":"Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform<\/i>\n <\/p>\n

\n Built on Illumina’s powerful sequencers, new, disruptive omics solutions surpass industry standards for <\/i>
\n quality, scale, accuracy, and replicability<\/i>\n <\/p>\n

\n
\n SAN DIEGO<\/span>
\n <\/span>, Feb. 24, 2025<\/span><\/span> \/PRNewswire\/ — Illumina, Inc. (NASDAQ: ILMN) has unveiled a series of roadmap innovations, establishing the industry’s largest portfolio of omics solutions and sequencing applications. The solutions \u2013 spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software \u2013 will enable researchers to derive breakthrough insights around the drivers of disease. The new omics solutions surpass industry standards for scale, accuracy, and reliability because they are built on Illumina’s powerful sequencers, known for unmatched quality, consistency, and accuracy. The expanded multiomics portfolio will be presented today at the Advances in Genome Biology and Technology (AGBT)\u00a0General Meeting.<\/p>\n

\n

\n
\n \"Illumina
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“Illumina is the backbone of innovation for our industry, and we’re bringing disruptive, new solutions at a scale that only Illumina can deliver,” said Jacob Thaysen<\/span>, CEO of Illumina. “Illumina has paved the way for genomic breakthroughs, and now we are committed to accelerating advances on all frontiers of multiomics. Our technologies will help researchers gain a more complete understanding of biology, accelerating the translation of data into insights that can truly unlock precision health care.”<\/p>\n

“Illumina is doing what we do best: breaking new ground and setting the standard,” said Steve Barnard<\/span>, PhD, chief technology officer of Illumina. “Just as researchers have come to rely on an accurate, complete and comprehensive view of the genome, Illumina is now bringing the same attributes to the entire range of multiomics exploration, with the complete workflows needed to ensure value and usability. These solutions represent a leap forward in discovery, and we can’t wait to bring these solutions into more labs.”<\/p>\n

\n Illumina’s announcements at AGBT drive new scale, quality in multiomic discovery<\/b>\n <\/p>\n

Illumina’s AGBT Gold Sponsor Workshop today will showcase the latest advances across a range of multiomic capabilities enabled on Illumina’s sequencing platforms and supported by its new multimodal data analysis platform. The updates illustrate Illumina’s continued commitment to provide customers with end-to-end solutions that streamline and simplify workflows, and its growing portfolio of multiomics offerings, which includes Illumina Single Cell and Illumina Protein Prep.<\/p>\n